Small Molecule Strategies to Induce Antigen-Specific B Cell Tolerance

Developing novel multivalent small molecules that selectively silence or eliminate the autoantibody-producing B cells driving autoimmune disease.
Ongoing Other Autoantibodies Autoantigens B Cell Biology Biological & Mechanistic Immune Tolerance Precision Medicine Therapeutic Development Translational & Clinical

Funding Year: 2024

Project Overview

Most autoimmune treatments suppress the immune system broadly, leaving patients vulnerable to infection and other side effects. This project takes a precise alternative approach: developing multivalent small molecules that target specific populations of autoantibody-producing B cells based on their epitope specificity, while leaving healthy antibody-producing cells intact. These molecules can be augmented with immunosuppressive motifs to silence or eliminate pathogenic antigen-specific memory B cells. By pharmacologically targeting the underlying immunopathology rather than broadly suppressing immunity, this approach has the potential to treat or cure antibody-driven autoimmune diseases without the drawbacks of conventional immunosuppression.

Impact & Innovation

Precision silencing of the B cells that drive autoimmunity.

 

By designing multivalent molecules that target autoantibody-producing B cells by epitope specificity — leaving healthy immune cells intact — this project offers a path to treating or curing antibody-driven autoimmune diseases without broad immunosuppression.

  • Demonstrates that antigen-specific B cell populations can be selectively suppressed or eliminated using novel multivalent compounds augmented with immunosuppressive motifs
  • Generates entirely novel IP through small molecule compounds protected by Yale Ventures, building on the Spiegel Laboratory’s established track record in translational chemistry
  • Advances the Consortium’s From Mechanistic Insight to Translation pillar by converting a precision immunology concept into a pharmacological platform with broad applicability across antibody-driven autoimmune diseases
Research Approach

A framework designed for discovery

This project applies synthetic chemistry and B cell immunology to design, develop, and validate multivalent small molecules capable of selectively silencing or eliminating autoantigen-specific B cells. The work moves from molecular design through functional validation, with a translational focus on antibody-driven autoimmune diseases.


Design and synthesis of multivalent molecules targeting specific B cell populations by epitope specificity; augmentation of lead compounds with immunosuppressive motifs to enable silencing or elimination of pathogenic antigen-specific memory B cells; and in vitro and in vivo functional validation of B cell suppression and elimination activity.

B cell population profiling datasets distinguishing autoantigen-specific from healthy antibody-producing cells, in vitro functional assay data measuring selective B cell suppression and elimination, and in vivo autoimmune disease model datasets assessing therapeutic efficacy and immune specificity of lead compounds.

Validation of antigen-specific B cell targeting as a pharmacological strategy for treating antibody-driven autoimmune disease without broad immunosuppression, with entirely novel compounds protected by Yale Ventures IP. Lead compounds are designed for advancement toward preclinical and clinical development across multiple autoimmune indications.


Investigators & Institutions

Powering the science

Principal Investigator

David A. Spiegel, MD, PhD, Colton Consortium Member

Professor, Department of Chemistry, Yale Faculty of Arts and Sciences (FAS), Yale University

Colton Centers & Institutions

Colton Center for Autoimmunity at Yale University